Cross-Sector entity
Of the tracked stories, 3 of 3 also mention 5th U.S. Circuit Court of Appeals, the most common co-covered peer. The clearest coverage concentration is fda-approval: 1 of 3 stories, with the rest divided among 2 other categories. Society of Family Planning appears in 3 tracked Cross-Sector stories published from September 9, 2026 through September 12, 2026.
3 verified stories tracked
Last mentioned: Sep 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 3 of 3 also mention 5th U.S. Circuit Court of Appeals, the most common co-covered peer. The clearest coverage concentration is fda-approval: 1 of 3 stories, with the rest divided among 2 other categories. Society of Family Planning appears in 3 tracked Cross-Sector stories published from September 9, 2026 through September 12, 2026. Each carries 2 original sources on average.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Society of Family Planning. Shared-story counts are live from our verified record — not editorial picks.
Medication abortion using mifepristone and misoprostol is now the standard of care for most US abortions. A 5th Circuit ruling could disrupt telehealth prescribing and shield-law access for 770 to 900 Louisiana women each month. The FDA's concurrent safety review adds clinical-policy uncertainty.
Source: nbcsandiego.com · nbcwashington.com
Healthcare providers and health IT teams face potential disruption as the 5th Circuit weighs barring telehealth prescribing of mifepristone. Survey data show 770-900 Louisiana women per month used pills prescribed online or by out-of-state clinicians in 2025.
The biopharmaceutical sector is watching the 5th Circuit review of mifepristone's FDA prescribing rules. At least 60% of U.S. abortions use the two-drug regimen, making the drug's distribution and label conditions a high-stakes regulatory precedent.
Source: timesargus.com · bozemandailychronicle.com
